France is observing October Rose, a month dedicated to raising awareness about breast cancer, highlighting the importance of early detection and treatment. However, this period has also brought difficult news for many patients. A recent official decree announced that certain medications will no longer be covered by France's social insurance system. Specifically, the substances Zoladex® 10.8 mg (goserelin acetate) and Zoladex® 3.6 mg, which are injectable implants used in the treatment of hormone-dependent breast cancer and metastatic prostate cancer, will be removed from the list of reimbursable medicines starting December 15, 2026. These drugs are currently fully covered by the French Health Insurance, with public prices of 256.66 euros for the 10.8 mg version and 86.03 euros for the 3.6 mg version. The manufacturer, Astrazeneca, requested the removal, citing the need to adjust to the French market's challenges and ensure the drug's long-term availability. Breast cancer continues to be the most common cancer among women, with an estimated 61,214 new cases in France in 2023. Prostate cancer, which primarily affects men, saw an estimated 59,885 new cases in 2018. The decision by Astrazeneca to withdraw reimbursement for Zoladex® has raised concerns among patients and healthcare professionals. The company stated that the current price of the drug no longer allows for sustainable availability within the framework of the French reimbursement system. This change means that after December 15, the medication will no longer be covered by the Health Insurance, though it will still be available for purchase in pharmacies at the patient's expense. Patients have been given a few months to consult with their oncologists to explore alternative treatments that are covered by the Health Insurance. This transition period is intended to help patients manage the change without disrupting their medical care. However, any modifications to a treatment plan should be made only after consulting a healthcare professional. The decision highlights the ongoing challenges in balancing pharmaceutical pricing, healthcare accessibility, and the sustainability of medical treatments within public health systems.